Evidence mapPaperPMID 41838283Full record

ReviewMolecular biology reports2026

Nrf3: an emerging player in cancer, inflammation, and cellular homeostasis.

Deniz Kilicaslan, Meliha Burcu Irmak-Yazicioglu, Erna Copuroglu

Abstract readReview
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Deniz KilicaslanDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-8113-219X
Meliha Burcu Irmak-YaziciogluDepartment of Molecular Biology and Genetics, Faculty of Science and Literature, Haliç University, Istanbul, Turkey. burcuyazicioglu@halic.edu.tr.ORCID http://orcid.org/0000-0002-1651-305X
Erna CopurogluGraduate Program of Molecular Biology and Genetics, Institute of Graduate Studies, Haliç University, Istanbul, Turkey.ORCID http://orcid.org/0009-0008-6783-5965

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear factor erythroid 2-related factor 3 (Nrf3) is a transcription factor of the CNC-bZIP family that plays a critical role in managing cellular stress, redox balance, and internal homeostasis. Initially localized to the endoplasmic reticulum, Nrf3 undergoes a sophisticated activation process to reach the nucleus and regulate gene expression. Emerging evidence identifies Nrf3 as a multifaceted and context-dependent regulator whose biological impact varies significantly across different tissues and disease states. In cancer biology, Nrf3 exhibits a dual role by acting as either an oncogene or a tumor suppressor. In many malignancies, such as colorectal and pancreatic cancers, it promotes tumor growth by driving cell cycle progression, metabolic adaptation, and cancer cell survival. Conversely, in other contexts like breast cancer, Nrf3 can inhibit tumor progression by increasing stress signals and suppressing pathways that lead to cell migration. Beyond its role in oncology, Nrf3 coordinates responses to inflammation and metabolic shifts, often under the control of various cellular signals and microRNAs. This review highlights its importance in maintaining cellular health and underscores its potential as a clinical biomarker and therapeutic target, while calling for further research to fully clarify its diverse biological functions.

Indexed as

InflammationNeoplasmsAnimalsGene Expression Regulation, NeoplasticHomeostasisHumansMetabolic ReprogrammingSignal TransductionAntioxidantCancerCap’n CollarNrf3

Identifiers

PMID41838283
PMCPMC12992410

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.